<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02179177</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048953</org_study_id>
    <nct_id>NCT02179177</nct_id>
  </id_info>
  <brief_title>Apixaban in Patients With Sickle Cell Disease</brief_title>
  <official_title>Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nirmish Shah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with SCD, the use of low dose anticoagulation as an outpatient may lead to a
      significant decrease in morbidity and as a result, decrease healthcare utilization and costs.
      This study attempts to critically avoid admissions by reducing daily pain scores and pain
      crisis as an outpatient by use of a novel oral anticoagulant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is not only significant morbidity associated with patients with SCD, but also costs
      associated with the numerous hospitalizations. Small studies have been unable to show clear
      benefit of the use of low dose anticoagulation in SCD due to limited sample size or the
      inclusion of very specific populations. However, studies have shown a decrease in the level
      of elevated prothrombotic markers with anticoagulation, and one study using full dose
      anticoagulation in patients with a generally milder form of SCD (with high protective
      hemoglobin) showed more rapid decrease in clinical pain with use of anticoagulation,
      suggesting a possible benefit of such therapy. Due to the paucity of data to support
      therapeutic dose LMWH in the more severe forms of SCD seen in the United States, we have
      chosen prophylactic dose anticoagulation. This study proposal attempts to critically avoid
      admissions by reducing daily pain scores and pain crisis as an outpatient by use of a novel
      oral anticoagulant.

      The development of novel anticoagulants such as oral direct factor Xa (FXa) inhibitors allows
      the realistic use of daily prophylactic dosing as an outpatient. Past studies as detailed
      earlier have been limited by attempts to use subcutaneous injections or frequent, close
      monitoring for acenocoumarol treatment, both which are not ideal for chronic daily use.
      Furthermore, the use of global assays such calibrated automated thrombography (CAT) have
      shown further details about thrombin generation in a population which is hypercoagulable at
      baseline.

      This is a double blind, parallel group, placebo controlled feasibility study with an
      enrollment target of 25 patients (12 per arm). All subjects that meet inclusion criteria as
      an outpatient, following a 1 month observation, will be randomized to receive an oral
      prophylactic dose factor Xa inhibitor (Apixaban 2.5mg po bid) or placebo for 6 months.
      Subjects will return for a 30 day (+/- 5 days) follow-up visit after the End of Treatment
      (EOT) visit. Initial randomization will occur by computerized randomization technique by the
      investigational drug services (IDS) at Duke University Medical Center.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding has been exhausted
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">September 3, 2017</completion_date>
  <primary_completion_date type="Actual">September 3, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain as Measured by Visual Analog Scale (VAS)</measure>
    <time_frame>Month 1 to Month 8</time_frame>
    <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Thrombin Generation Using D-dimer Measurement as a Surrogate</measure>
    <time_frame>Enrollment to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Pain Scores While Hospitalized as Measured by VAS</measure>
    <time_frame>up to 8 months</time_frame>
    <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other. Secondary analysis will be performed to evaluate differences when patients are hospitalized and on study drug versus placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hospitalizations During Treatment</measure>
    <time_frame>up to 8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Vaso-occlusive Crisis</condition>
  <condition>Reduction in Hospitalizations</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug Apixaban 2.5mg taken by mouth twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Drug is taken by mouth twice a day for 6 months</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  documented HgbSS, SC or HgbS-beta0 thalassemia,

          -  age ≥18 years old and ≤80,

          -  seen in outpatient clinic ≥2 times in past year

          -  seen for an acute care visit (hospitalization, emergency department, or day hospital
             visit) for pain &gt;2 times in the past year.

        Exclusion Criteria:

          -  Hospitalization or day hospital visit for pain crisis within the past 2 weeks

          -  Patients with ≥10 acute care visits within the past year will be excluded

          -  Creatinine &gt;3.0 mg/dL

          -  creatinine ≥1.5 mg/dL AND weight ≤60 kg

          -  chronic use of antiplatelet or anticoagulation medication

          -  Patients with known vasculopathy or Moya-Moya

          -  platelet count &lt;100 X 109/L

          -  AST or ALT &gt;3 times normal

          -  chronic red blood cell transfusions (scheduled transfusions)

          -  packed red blood cell transfusion within the past 2 months

          -  Use of CYP3A4 and P-gp inhibitor medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nirmish Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <results_first_submitted>February 24, 2020</results_first_submitted>
  <results_first_submitted_qc>February 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2020</results_first_posted>
  <disposition_first_submitted>March 26, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 15, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 22, 2019</disposition_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Nirmish Shah</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vaso-occlusive crisis</keyword>
  <keyword>Reduction in hospitalizations</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02179177/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with sickle cell disease were enrolled as an outpatient in clinic while at baseline pain from January 2015 to September 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Apixaban</title>
          <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Apixaban</title>
          <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="6.2"/>
                    <measurement group_id="B2" value="33" spread="3.9"/>
                    <measurement group_id="B3" value="31.5" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain as Measured by Visual Analog Scale (VAS)</title>
        <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other.</description>
        <time_frame>Month 1 to Month 8</time_frame>
        <population>Two participants in each group (Apixaban and Placebo) did not return for Month 8 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain as Measured by Visual Analog Scale (VAS)</title>
          <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other.</description>
          <population>Two participants in each group (Apixaban and Placebo) did not return for Month 8 visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="0.5"/>
                    <measurement group_id="O2" value="0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Thrombin Generation Using D-dimer Measurement as a Surrogate</title>
        <time_frame>Enrollment to 2 months</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thrombin Generation Using D-dimer Measurement as a Surrogate</title>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Pain Scores While Hospitalized as Measured by VAS</title>
        <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other. Secondary analysis will be performed to evaluate differences when patients are hospitalized and on study drug versus placebo.</description>
        <time_frame>up to 8 months</time_frame>
        <population>Two participants from each group (Apixaban and Placebo) did not return for Month 8 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Pain Scores While Hospitalized as Measured by VAS</title>
          <description>The primary pain assessment tool will be a 10-cm horizontal visual analog scale (VAS), with &quot;0&quot; corresponding to no pain at one end and &quot;10&quot; indicating the worst pain at the other. Secondary analysis will be performed to evaluate differences when patients are hospitalized and on study drug versus placebo.</description>
          <population>Two participants from each group (Apixaban and Placebo) did not return for Month 8 visit.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="3.4"/>
                    <measurement group_id="O2" value="6.6" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hospitalizations During Treatment</title>
        <time_frame>up to 8 months</time_frame>
        <population>Two participants from each group (Apixaban and Placebo) did not return for 8 Month visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban</title>
            <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hospitalizations During Treatment</title>
          <population>Two participants from each group (Apixaban and Placebo) did not return for 8 Month visit.</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="3.3"/>
                    <measurement group_id="O2" value="1.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Apixaban</title>
          <description>Active drug Apixaban 2.5mg taken by mouth twice a day
Apixaban: Drug is taken by mouth twice a day for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Sugar pills that look like Apixaban that will be taken by mouth twice a day
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle Cell Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sickle Cell Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nirmish Shah, MD</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-5178</phone>
      <email>nirmish.shah@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

